Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erwan Bezard

Showing results (111-120 of 298) with videos related to

Pageof 30
Sort By:
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|April 25, 2008
The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's diseaseStefan Schuster, Agnès Nadjar, Jun Tang Guo, et al.
Neurobiology of Disease|June 28, 2014
RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's diseaseWai Kin D Ko, Marie-Laure Martin-Negrier, Erwan Bezard, et al.
Neuroscience Letters|December 29, 2007
Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's diseaseDieter Scheller, Christine Stichel-Gunkel, Hermann Lübbert, et al.
Neurobiology of Disease|September 3, 2018
G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged miceSalvatore Novello, Ludovico Arcuri, Sandra Dovero, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|May 18, 2019
Assessment of plasma creatine kinase as biomarker for levodopa-induced dyskinesia in Parkinson's diseaseAnna Delamarre, François Tison, Qin Li, et al.
Autophagy|January 14, 2016
Nanoparticles restore lysosomal acidification defects: Implications for Parkinson and other lysosomal-related diseasesMathieu Bourdenx, Jonathan Daniel, Emilie Genin, et al.
Progress in Neurobiology|January 14, 2020
Corrigendum to "Dystonia and dopamine: From phenomenology to pathophysiology" [Prog. Neurobiol. 182 (November) (2019), 101678, 18]Bastien Ribot, Jérome Aupy, Marie Vidailhet, et al.
Neurochemistry International|September 1, 2004
Partial bilateral mesencephalic lesions affect D1 but not D2 binding in both the striatum and cortexElsa Pioli, Reinhard Sohr, Wassilios Meissner, et al.
Heliyon|January 1, 2021
Gastrointestinal and metabolic function in the MPTP-treated macaque model of Parkinson's diseaseAnna Delamarre, Cliona MacSweeney, Rie Suzuki, et al.
Methods (San Diego, Calif.)|March 14, 2019
Nanoscale exploration of the extracellular space in the live brain by combining single carbon nanotube tracking and super-resolution imaging analysisChiara Paviolo, Federico N Soria, Joana S Ferreira, et al.
Pageof 30

Showing results (111-120 of 298) with videos related to

Sort By:
Pageof 30
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|April 25, 2008
The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's diseaseStefan Schuster, Agnès Nadjar, Jun Tang Guo, et al.
Neurobiology of Disease|June 28, 2014
RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's diseaseWai Kin D Ko, Marie-Laure Martin-Negrier, Erwan Bezard, et al.
Neuroscience Letters|December 29, 2007
Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's diseaseDieter Scheller, Christine Stichel-Gunkel, Hermann Lübbert, et al.
Neurobiology of Disease|September 3, 2018
G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged miceSalvatore Novello, Ludovico Arcuri, Sandra Dovero, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|May 18, 2019
Assessment of plasma creatine kinase as biomarker for levodopa-induced dyskinesia in Parkinson's diseaseAnna Delamarre, François Tison, Qin Li, et al.
Autophagy|January 14, 2016
Nanoparticles restore lysosomal acidification defects: Implications for Parkinson and other lysosomal-related diseasesMathieu Bourdenx, Jonathan Daniel, Emilie Genin, et al.
Progress in Neurobiology|January 14, 2020
Corrigendum to "Dystonia and dopamine: From phenomenology to pathophysiology" [Prog. Neurobiol. 182 (November) (2019), 101678, 18]Bastien Ribot, Jérome Aupy, Marie Vidailhet, et al.
Neurochemistry International|September 1, 2004
Partial bilateral mesencephalic lesions affect D1 but not D2 binding in both the striatum and cortexElsa Pioli, Reinhard Sohr, Wassilios Meissner, et al.
Heliyon|January 1, 2021
Gastrointestinal and metabolic function in the MPTP-treated macaque model of Parkinson's diseaseAnna Delamarre, Cliona MacSweeney, Rie Suzuki, et al.
Methods (San Diego, Calif.)|March 14, 2019
Nanoscale exploration of the extracellular space in the live brain by combining single carbon nanotube tracking and super-resolution imaging analysisChiara Paviolo, Federico N Soria, Joana S Ferreira, et al.
Pageof 30